Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
Los Bonos 1, 2 y 3 se encuentran actualmente cerrados. En las próximas semanas se proporcionará más información acerca de su apertura de cara a 2025.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
67
resultados
Última actualización
20/12/2024 [10:14:00]
Resumen de: US2024408244A1
Provided herein are compositions and methods for diagnosing, prognosing, and treating neurodegenerative diseases in a male and female subject at risk of or diagnosed with a neurodegenerative disease. In particular, provided herein are customized metabolite analyses for characterizing and treating neurodegenerative diseases in specific subject groups from a sample from said subject.
Resumen de: WO2024253424A1
The present invention relates to a humanized antibody specifically binding to a human TREM2 protein and a use thereof. The humanized antibody is prepared using a CDR grafting technology in which a complementarity determining region (CDR) corresponding to an antigen binding site of a mouse antibody variable region is transplanted into a human germline-derived sequence, thereby securing the humanized antibody specifically binding to TREM2. The obtained humanized antibody was confirmed for binding ability to an antigen and biological activity, and a chimeric antibody in the form of IgG1 was converted into the forms of IgG2 and IgG4 and produced, and confirmed for binding ability to an antigen and biological activity. With a high affinity for TREM2, the present invention can develop an antibody-based diagnosis system capable of diagnosing TREM2 as a biomarker of various Alzheimer's dementia. In addition, since existing therapeutic agents for Alzheimer's disease are mostly symptom-alleviating agents due to the temporary regulation of neurotransmitters, it is considered that the development of antibodies targeting TREM2 can lead to the development of promising new drugs having substantial therapeutic effects.
Resumen de: WO2024253420A1
The present invention relates to a human antibody specifically binding to a human TREM2 protein, and use thereof. The human monoclonal antibody specifically binding to TREM2 has been discovered through biopanning using a human synthetic antibody phage display library, and the antigen binding ability and biological activity of the discovered antibody have been identified. The present invention has a high affinity for TREM2, and thus enables the development of an antibody-based diagnosis system capable of diagnosing TREM2 as a biomarker of various Alzheimer's dementia. In addition, since a conventional therapeutic agent for Alzheimer's disease is mostly a symptom reliever through the temporary regulation of neurotransmitters, it is considered that the development of antibodies targeting TREM2 can lead to the development of promising new drugs having substantial therapeutic effects.
Resumen de: WO2024254159A1
Disclosed herein are methods for diagnosing Alzheimer's disease in a subject that involves administering to the subject an imaging agent comprising hyperpolarized pyruvate having a nuclear magnetic resonance (NMR)-detectable nucleus; applying radiation to the brain of the subject, wherein the radiation has a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; detecting magnetic resonance signals in the brain of the subject from nuclear spin transitions in the NMR-detectable nucleus to produce a spectrum measuring bicarbonate (Bic) and lactate (Lac) metabolites; and calculating a Bic/Lac ratio from the measured metabolites, wherein a reduced Bic/Lac ratio compared to control is an indication that the subject has Alzheimer's disease.
Resumen de: US2024409570A1
Disclosed herein is a compound and its use for the prognosis or diagnosis of neurodegenerative diseases. The compound has the structure of formula (I),According to embodiments of the present disclosure, the neurodegenerative disease may be an Alzheimer's disease (AD), Parkinson disease (PD), Huntington's disease (HD), frontotemporal dementia (FTD), Friedreich's ataxia, age-related macular degeneration, or Creutzfeldt-Jakob disease.
Resumen de: MX2024009597A
Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as susceptible and at risk for developing amyloid-beta and cognitive dysfunction using tau-PET imaging based on regional tau PET measures.
Resumen de: MX2024009492A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Resumen de: CN118613263A
Described herein are improvements relating to the analysis of IGF-1 function, modulation and their use in disease management of non-neurological and/or neurological disorders. More specifically, the invention relates to a method for the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as plasma biomarkers for predicting the risk and recovery of non-neurological and/or neurological conditions associated with IGF-1 dysfunction, and the use of cGP-containing animal, marine organism or fungus-based materials such as hydrolysed bovine collagen and marine organism collagen, concentrates/extracts of mushrooms and seaweed and plant-based cGPMAXTM for the treatment of said non-neurological and/or neurological disorders. The method uses cGP and cGP/IGF-1 molar ratios to indirectly more accurately measure the IGF-1 function in vivo, as well as means to adjust the cGP and cGP/IGF-1 molar ratios (thereby adjusting the active IGF-1 concentration) and means to normalize the cGP and cGP/IGF-1 molar ratios (thereby normalizing the active IGF-1 concentration), and specific methods of treatment for individuals having a lower or reduced cGP level relative to a standard baseline data set. The cGPMAXTM prepared by supplementing bovine collagen effectively improves the sensory function of patients with diabetic neuropathy.
Resumen de: CN116908452A
The present disclosure relates to systems and methods for protein crown sensor arrays for early detection of disease. Sensor arrays for detecting biomolecules and methods of using the same are provided. In some embodiments, a sensor array is capable of detecting a disease state of a subject.
Resumen de: US2024398822A1
The disclosure provides compounds, salts and methods of use thereof for the prevention, treatment, delay of onset and management of Alzheimer's disease.
Resumen de: US2024398824A1
Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.
Resumen de: US2024402194A1
Antibodies and diagnostic assays for detecting synucleinopathies are provided. The assay is specific and compatible with different biological samples (brain, cerebrospinal fluid, blood, saliva, urine, skin, nasal swabs, or feces).
Resumen de: WO2023144765A1
Method for diagnosing Alzheimer's disease in an individual, comprising the steps of providing at least one serum sample derived from the individual, providing at least one preparation of phage clones expressing peptides that mimic conformational epitopes of the Aβ- 42 peptide, reacting said at least one serum sample with said at least one preparation of phage clones expressing peptides that mimic conformational epitopes of Aβ-42, so that antibodies that may be present in said serum and are directed against the Aβ-42 peptide bind to the peptides expressed by phage clones of said preparation of phage clones, detecting, by real-time PCR technique, the quantity of phage clones of said preparation to which said antibodies have bound, and determining, based on the quantity of phage clones of said preparation to which said antibodies have bound, whether the individual from whom said serum sample was derived suffers from Alzheimer's disease.
Resumen de: EP4296670A2
Provided herein is the use of a compound of Formula I:or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: US2024393348A1
Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.
Resumen de: WO2024242393A1
Embodiments relate to a method for calculating the Alzheimer's disease risk probability of a subject on the basis of blood information about the subject and a system for performing same, the method comprising the steps of: acquiring the blood information about the subject; acquiring demographic information about the subject; and calculating the probability of the subject being amyloid positive by inputting at least a portion of the blood information and demographic information about the subject to a trained risk prediction model.
Resumen de: WO2024240079A1
The present invention relates to the technical field of medicines. Disclosed are a detection marker, a diagnostic marker, a use thereof, and a kit. In the present invention, PPP2R5C is used as a detection marker for the preclinical stage of Alzheimer's disease (AD) and as a diagnostic marker for mild cognitive impairment and AD; thus, the problems of detection defects and lack of effective blood biomarkers in lumbar puncture and PET-CT detection methods used in early diagnosis of AD are solved.
Resumen de: US2024393350A1
Method for the early diagnosis and the monitoring of the evolution/regression of neurodegenerative pathologies, said method providing for the quantification of a, biomarker for said pathologies in a fluid that was previously drawn from a, patient, said fluid being selected from among: cerebrospinal fluid; serum; urine; post mortem cerebral tissues and cellular lysates, said method being characterized in that the quantified biomarker is selected from among native proNGF; modified proNGF, the latter being proNGF in its forms with higher molecular weight, including forms of 39-40 kDa and 45-50 kDa; NGF; and the proNGF/NGF ratio, said method sequentially providing for the following steps of Preparation of the biological sample. Definition of the calibration curve: Execution of run and interpolation.
Resumen de: AU2023276707A1
Provided herein are methods and kits for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia. Also provided are methods of predicting or measuring a response to a treatment by measuring biomarker levels in a sample, and methods of modulating biomarker levels.
Resumen de: US2024393349A1
Provided are a method of simply detecting Alzheimer's disease (AD) and a method of simply stratifying AD pathological phases, and a reagent that can be used for the methods, based on the fact that measurement of a protein contained in extracellular vesicles enables detection of Alzheimer's disease and stratification of AD pathological phases.
Resumen de: WO2024239122A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Resumen de: WO2024243435A2
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: KR20240167329A
실시 예들은 상기 대상자의 혈액 정보를 획득하는 단계; 상기 대상자의 인구통계정보를 획득하는 단계; 및 미리 학습된 위험도 예측 모델에 상기 대상자의 혈액 정보 및 인구통계정보 중 적어도 일부를 입력하여 상기 대상자의 아밀로이드 양성 확률을 산출하는 단계를 포함하는, 대상자의 혈액 정보에 기초하여 대상자의 알츠하이머병 위험 확률을 산출하는 방법 및 이를 수행하는 시스템에 관한 것이다.
Resumen de: KR20240167314A
실시 예들은 상기 대상자의 혈액 정보를 획득하는 단계; 상기 대상자의 인구통계정보를 획득하는 단계; 및 미리 학습된 위험도 예측 모델에 상기 대상자의 혈액 정보 및 인구통계정보 중 적어도 일부를 입력하여 상기 대상자의 아밀로이드 양성 확률을 산출하는 단계를 포함하는, 대상자의 혈액 정보에 기초하여 대상자의 알츠하이머병 위험 확률을 산출하는 방법 및 이를 수행하는 시스템에 관한 것이다.
Nº publicación: KR20240167334A 26/11/2024
Solicitante:
주식회사브레디스헬스케어
Resumen de: KR20240167334A
실시 예들은 상기 대상자의 혈액 정보를 획득하는 단계; 상기 대상자의 인구통계정보를 획득하는 단계; 및 미리 학습된 위험도 예측 모델에 상기 대상자의 혈액 정보 및 인구통계정보 중 적어도 일부를 입력하여 상기 대상자의 아밀로이드 양성 확률을 산출하는 단계를 포함하는, 대상자의 혈액 정보에 기초하여 대상자의 알츠하이머병 위험 확률을 산출하는 방법 및 이를 수행하는 시스템에 관한 것이다.
BOPI
Sede Electrónica
